Exploring the shared mechanism of fatigue between systemic lupus erythematosus and myalgic encephalomyelitis/chronic fatigue syndrome: monocytic dysregulation and drug repurposing. — CFSMEATLAS
Exploring the shared mechanism of fatigue between systemic lupus erythematosus and myalgic encephalomyelitis/chronic fatigue syndrome: monocytic dysregulation and drug repurposing.
Zheng, Daisi, Li, Xiaolong, Wang, Peicheng et al. · Frontiers in immunology · 2024 · DOI
Quick Summary
Researchers discovered that ME/CFS and lupus (SLE) may share similar immune problems, particularly involving immune cells called monocytes that become overactive and produce excess inflammation. By studying genes and immune cells from both diseases, they identified five key inflammatory proteins that appear important in fatigue, and they predict that certain existing drugs—particularly N-acetyl-L-cysteine and camptothecin—might help reduce this inflammation.
Why It Matters
This study addresses a critical gap by proposing a shared biological mechanism for fatigue across two conditions affecting millions globally. Identifying monocytic dysregulation as a common pathway could enable development of targeted treatments and help validate ME/CFS as a distinct biological disorder with measurable immune abnormalities.
Observed Findings
58 overlapping genes between SLE and ME/CFS, primarily in innate immunity and inflammatory pathways.
Five key targets (IL1β, CCL2, TLR2, STAT1, IFIH1) were identified and significantly upregulated in activated monocytes.
Single-cell sequencing confirmed these targets are enriched in classical monocytes rather than other immune cell types.
RT-qPCR validation confirmed upregulation of key targets in the THP-1 monocyte inflammation model.
Ten candidate drugs were predicted through network analysis, with simvastatin and camptothecin showing high molecular affinity.
Inferred Conclusions
SLE and ME/CFS share overlapping immune and inflammatory pathways centered on monocytic dysregulation.
Classical monocytes may be crucial mediators linking systemic inflammation to fatigue in both conditions.
N-acetyl-L-cysteine and camptothecin are computational candidates warranting further experimental and clinical validation.
Targeting monocyte activation and the identified inflammatory proteins represents a potential therapeutic strategy for fatigue in both diseases.
Remaining Questions
Do these inflammatory proteins directly cause fatigue, or are they merely associated markers of disease activity?
What This Study Does Not Prove
This study does not prove that these inflammatory proteins directly cause fatigue, only that they are associated with both diseases. The in vitro cell model may not fully reflect the complex biological environment in living patients, and computational drug predictions require experimental validation before clinical use.